Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

Appeal

AstraZeneca : Appeal letter (MSWord 59 KB)

AstraZeneca : Scrutiny letter (MSWord 82 KB)

AstraZeneca : Response to scrutiny letter (MSWord 76 KB)

AstraZeneca : Final scrutiny letter (MSWord 153 KB)

Peaches Womb Cancer Trust : Appeal letter (MSWord 69 KB)

Peaches Womb Cancer Trust : Scrutiny letter (MSWord 79 KB)

Final draft guidance

Final draft guidance (PDF 245 KB)

Committee papers (PDF 992 KB)

Public committee slides (PDF 473 KB)

Draft guidance

Draft guidance (downloadable version) (PDF 273 KB)

Draft guidance (online commenting)

Committee papers (PDF 9.11 MB)

Public committee slides (PDF 1008 KB)

Final scope (PDF 131 KB)

Final stakeholder list (PDF 135 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 152 KB)

Draft scope post referral (PDF 185 KB)

Draft matrix post referral (PDF 165 KB)